Developer docs
API playgroundTry for free, no card

Search company profiles

ACIST

Full company profile

uuid0009w7g

Namestring
ACIST
Legal namestring
ACIST Medical Systems, Inc.
Websiteurl
acist.com
Company typeenum
Private
Founded yearint
1991
Descriptiontext

ACIST Medical Systems, founded in 1991 by Dr. Robert F. (Bob) Wilson and headquartered in Eden Prairie, Minnesota, designs and manufactures cardiovascular diagnostic imaging and physiological assessment technologies used in catheterization laboratories. Its product portfolio is organized around three clinical workflows: angiography/contrast management (ACIST CVi and the next-generation ACIST Pro), intravascular imaging (ACIST HDi with Kodama HD IVUS catheter and HubVue PACS integration), and physiology (ACIST RXi and RXi Mini systems with Navvus II microcatheters and the ACIST dPR non-hyperemic pressure ratio algorithm). The platforms are designed to reduce contrast-induced acute kidney injury, improve IVUS-guided PCI optimization, and enable physiology-based coronary assessment without adenosine-induced hyperemia.

ACIST operates as a wholly-owned subsidiary of Bracco Group, an Italian diagnostic imaging company that acquired ACIST in 2001; SVMI and the HDi IVUS technology were acquired by ACIST in 2012 to extend the portfolio beyond contrast injection. The business generates revenue through three streams: capital medical equipment sales (contrast injectors, IVUS consoles, FFR consoles) priced by quote, recurring consumable catheter revenue from Navvus II and Kodama disposable devices used per procedure, and multi-year service and support contracts offering preventive maintenance, loaner equipment, and on-site technical assistance. Distribution combines direct field sales in the Americas, EMEA (Netherlands headquarters), and APAC (Japan) with a multi-region distributor network covering more than 60 countries.

The company's go-to-market is anchored by enterprise sales targeting cath labs and cardiovascular departments in hospitals, supported by clinical education (webinars, KOL-led content, conference presence at TCT, ACC, ML CTO, and Scripps CV Interventions) and a medical education grant program. ACIST received U.S. FDA 510(k) clearance for ACIST Pro in May 2026 and CE Mark approval under the European MDR in February 2026, following an initial 2025 launch in Japan, and operates with ISO 13485, ISO 45001, and ISO 14001 certifications. Bracco Group reports approximately €1.29 billion in consolidated revenue across its full portfolio; ACIST-specific revenue is not separately disclosed.

Short descriptiontext

ACIST Medical Systems, a Bracco Group subsidiary founded in 1991, manufactures cardiovascular diagnostic technologies — contrast injection, IVUS imaging, and FFR/dPR physiology systems — for hospitals, cath labs, and interventional cardiologists across more than 60 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersEden Prairie, United States
HQ citystring
Eden Prairie
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contrast injection systems, intravascular ultrasound imaging, fractional flow reserve, interventional cardiology devices, cardiac catheterization equipment
Industry2 codes
1Contrast Media Injectors & Radiology Accessories
CodeHLAHABAKPrimaryYes
2Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
CodeHLAHAFAIPrimaryNo
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Interventional Cardiology Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Device Hardware Sales
TypeHardware Sales
Description

Sale of capital medical equipment including contrast injection systems (ACIST CVi, ACIST Pro), IVUS imaging systems (ACIST HDi), and FFR measurement systems (ACIST RXi, ACIST RXi Mini) to hospitals and cath labs.

acist.com
2Consumable Catheters
TypeHardware Sales
Description

Recurring revenue from disposable microcatheters including Navvus® II and Kodama® IVUS catheters used during procedures.

acist.com
3Service and Support Contracts
TypeManaged Services
Description

Technical support services including on-site assistance within 24 hours, next-day service loaner equipment, preventive maintenance and upgrades, offered as multi-year service packages.

acist.com
4Technical Support Services
TypeProfessional Services
Description

Customer service and technical support provided to European customers with on-site assistance and service loaner programs.

acist.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Medical device capital equipment - quotation-based pricing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Capital equipment pricing varies by system configuration. Quote-based pricing through ACIST sales representatives.

acist.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1ACIST CVi
Description

Contrast Delivery System for managing contrast delivery and minimizing risk of contrast-induced acute kidney injury (CI-AKI) in interventional cardiology procedures.

acist.com
+7 more records
Core offering1 text field

ACIST Medical Systems manufactures and sells cardiovascular diagnostic and interventional devices, including contrast injection systems (ACIST CVi and ACIST Pro), intravascular ultrasound imaging systems (ACIST HDi with Kodama catheters), and fractional flow reserve measurement systems (ACIST RXi with Navvus II microcatheters). These products are sold as capital equipment and disposable consumables to hospitals, cardiac catheterization laboratories, and interventional cardiologists for use in diagnostic and interventional cardiology, peripheral vascular, and structural heart procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 11 values shown
  • 45ml average reduction in contrast use
+10 more records
Product overview1 text field

ACIST Medical Systems, a Bracco Group company, provides a portfolio of diagnostic technologies for cardiovascular and peripheral vascular procedures. The product ecosystem centers on contrast management (ACIST Pro™, ACIST CVi®), intravascular imaging (ACIST HDi® with Kodama® catheter), and physiological assessment (ACIST RXi® with Navvus® II microcatheter and dPR feature). Products serve diagnostic and interventional cardiology, radiology, and vascular care across angiography, imaging, and physiology categories. The company operates from headquarters in Eden Prairie, Minnesota with European operations in the Netherlands and offices in Japan and Silicon Valley.

Product and service8 records
1ACIST Pro Diagnostic System
CategoryAngiography / Contrast Management
Description

Next-generation variable-rate contrast management solution for image-guided cardiovascular procedures that builds on ACIST CVi technology to deliver automated contrast delivery with reduced contrast use and improved patient outcomes; for interventional cardiologists and cath lab teams.

2ACIST CVi Contrast Delivery System
CategoryAngiography / Contrast Management
Description

Contrast Delivery System providing real-time, variable-flow control of contrast for precise and consistent contrast administration with built-in air column detection sensor alerts; for interventional cardiologists managing contrast volume and minimizing risk of contrast-induced acute kidney injury (CI-AKI).

3ACIST HDi High-Definition IVUS System
CategoryIntravascular Imaging
Description

60MHz high-definition intravascular ultrasound imaging system enabling optimized visualization for coronary and peripheral intervention strategy through three imaging modes (LumenView, SilkView, ClassicView) and an interactive compact console; for interventional cardiologists performing PCI optimization.

4ACIST RXi Rapid Exchange FFR System
CategoryPhysiology / FFR Measurement
Description

Rapid Exchange Fractional Flow Reserve system with dPR (Diastolic Pressure Ratio) for physiological assessment of coronary disease using a monorail microcatheter and 0.014 inch guidewire of choice; for interventional cardiologists assessing coronary stenosis severity.

5ACIST RXi Mini System
CategoryPhysiology / FFR Measurement
Description

Next-generation compact FFR measurement system engineered to integrate with hemodynamic systems and FFR software; for cath labs seeking simplified physiological assessment workflow.

6Navvus II Rapid Exchange FFR MicroCatheter
CategoryPhysiology / FFR Measurement (Catheter Consumable)
Description

Rapid Exchange FFR MicroCatheter with improved flexibility, reduced lesion entry profile, and 0.014 inch guidewire compatibility for navigation of complex coronary artery disease; used with ACIST RXi system for physiological assessment.

7Kodama HD IVUS Catheter
CategoryIntravascular Imaging (Catheter Consumable)
Description

HD IVUS Catheter with offset distal tip and VariFlex variable flexibility imaging window providing improved deliverability and optimized imaging for both coronary and peripheral vascular procedures; used with ACIST HDi console with 10x faster pullback at 10mm/sec.

8ACIST Service and Support Contracts
CategoryService & Support
Description

Multi-year technical support service packages including on-site assistance within 24 hours, next-day service loaner equipment, preventive maintenance, and upgrades for ACIST capital equipment installed in cath labs.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ACIST Medical Systems is a wholly-owned subsidiary of Bracco Group, a Milan-based international healthcare company and world leader in diagnostic imaging. Bracco Imaging S.p.A. acquired ACIST in 2001. Bracco Group has approximately 3,420 employees and annual consolidated revenues of around 1.29 billion euros with 86% from international sales.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

HeartFlow provides non-invasive FFR-CT analysis as an alternative to catheter-based FFR measurement, targeting the same clinical decision point as ACIST's RXi/dPR platform but with a fundamentally different (imaging-based) delivery model.

TypeBroad incumbent
Description

GE HealthCare offers contrast media injectors (OptiStar, EmpowerCTA) and broad imaging/IT infrastructure for cath labs and interventional suites, overlapping with ACIST's contrast management and PACS integration offerings at a much larger scale.

TypeBroad incumbent
Description

Philips owns Volcano (IVUS/FFR) and offers Azurion interventional suites with integrated imaging and contrast injection, competing with ACIST across both the capital equipment and physiology/imaging consumables in the cath lab.

TypeEmerging player
Description

CathWorks offers FFR-angio (cath lab-based non-invasive FFR) as a catheter-free alternative to traditional FFR measurement, representing emerging competitive pressure on ACIST's catheter-based physiology franchise.

TypeDirect peer
Description

Boston Scientific competes directly with ACIST in intravascular imaging through its OptiCross IVUS and AVVIGO guidance system, serving the same interventional cardiology cath lab customers with overlapping procedure-driven utilization.

TypeBroad incumbent
Description

Medrad (Bayer) is one of the largest manufacturers of contrast media injectors (Mark 7 Arterion) and interventional radiology equipment, competing head-to-head with ACIST's CVi/Pro in hospitals and imaging centers worldwide.

TypeDirect peer
Description

Opsens (acquired by Haemonetics) provides the OptoWire FFR measurement system, directly competing with ACIST's RXi/Navvus platform in catheter-based physiological assessment of coronary artery disease.

TypeDirect peer
Description

Guerbet is a leading contrast media and contrast injection systems manufacturer, directly competing with ACIST's CVi and Pro contrast management systems in hospital radiology and cardiology departments globally.

TypeBroad incumbent
Description

Siemens Healthineers provides Artis interventional angiography systems, contrast injectors, and broad imaging IT that overlaps with ACIST's offerings in hospital cath lab and interventional radiology environments.

TypeDirect peer
Description

Abbott competes with ACIST through its PressureWire FFR/iwFR physiology platform and OPTIS IVUS/OCT imaging systems, serving the same interventional cardiology procedure workflow with comparable catheter-based diagnostic offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ACIST

Interventional Cardiology Medical Devicesacist.com

ACIST Medical Systems, a Bracco Group subsidiary founded in 1991, manufactures cardiovascular diagnostic technologies — contrast injection, IVUS imaging, and FFR/dPR physiology systems — for hospitals, cath labs, and interventional cardiologists across more than 60 countries.

What ACIST does

ACIST Medical Systems, founded in 1991 by Dr. Robert F. (Bob) Wilson and headquartered in Eden Prairie, Minnesota, designs and manufactures cardiovascular diagnostic imaging and physiological assessment technologies used in catheterization laboratories. Its product portfolio is organized around three clinical workflows: angiography/contrast management (ACIST CVi and the next-generation ACIST Pro), intravascular imaging (ACIST HDi with Kodama HD IVUS catheter and HubVue PACS integration), and physiology (ACIST RXi and RXi Mini systems with Navvus II microcatheters and the ACIST dPR non-hyperemic pressure ratio algorithm). The platforms are designed to reduce contrast-induced acute kidney injury, improve IVUS-guided PCI optimization, and enable physiology-based coronary assessment without adenosine-induced hyperemia.

ACIST operates as a wholly-owned subsidiary of Bracco Group, an Italian diagnostic imaging company that acquired ACIST in 2001; SVMI and the HDi IVUS technology were acquired by ACIST in 2012 to extend the portfolio beyond contrast injection. The business generates revenue through three streams: capital medical equipment sales (contrast injectors, IVUS consoles, FFR consoles) priced by quote, recurring consumable catheter revenue from Navvus II and Kodama disposable devices used per procedure, and multi-year service and support contracts offering preventive maintenance, loaner equipment, and on-site technical assistance. Distribution combines direct field sales in the Americas, EMEA (Netherlands headquarters), and APAC (Japan) with a multi-region distributor network covering more than 60 countries.

The company's go-to-market is anchored by enterprise sales targeting cath labs and cardiovascular departments in hospitals, supported by clinical education (webinars, KOL-led content, conference presence at TCT, ACC, ML CTO, and Scripps CV Interventions) and a medical education grant program. ACIST received U.S. FDA 510(k) clearance for ACIST Pro in May 2026 and CE Mark approval under the European MDR in February 2026, following an initial 2025 launch in Japan, and operates with ISO 13485, ISO 45001, and ISO 14001 certifications. Bracco Group reports approximately €1.29 billion in consolidated revenue across its full portfolio; ACIST-specific revenue is not separately disclosed.

ACIST firmographics

Firmographics
Name
ACIST
Legal name
ACIST Medical Systems, Inc.
Website
https://acist.com
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
251–500 employees
Short description
ACIST Medical Systems, a Bracco Group subsidiary founded in 1991, manufactures cardiovascular diagnostic technologies — contrast injection, IVUS imaging, and FFR/dPR physiology systems — for hospitals, cath labs, and interventional cardiologists across more than 60 countries.
Ownership category
akta.pro rank

ACIST industry classification

Industry
Product category
Interventional Cardiology Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Contrast Media Injectors & Radiology Accessories (HLAHABAK)
akta.pro secondary industry
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

Keywords

  • Contrast injection systems
  • Intravascular ultrasound imaging
  • Fractional flow reserve
  • Interventional cardiology devices
  • Cardiac catheterization equipment

Where ACIST is headquartered

Location

Headquarters

HQ city
Eden Prairie
HQ country
United States
HQ region
North America

Offices4 records

Markets served

ACIST business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Hardware Sales: Sale of capital medical equipment including contrast injection systems (ACIST CVi, ACIST Pro), IVUS imaging systems (ACIST HDi), and FFR measurement systems (ACIST RXi, ACIST RXi Mini) to hospitals and cath labs.
  2. Consumable Catheters: Recurring revenue from disposable microcatheters including Navvus® II and Kodama® IVUS catheters used during procedures.
  3. Service and Support Contracts: Technical support services including on-site assistance within 24 hours, next-day service loaner equipment, preventive maintenance and upgrades, offered as multi-year service packages.
  4. Technical Support Services: Customer service and technical support provided to European customers with on-site assistance and service loaner programs.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractMedical device capital equipment - quotation-based pricing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

ACIST product offering

Product offering

Core offering

ACIST Medical Systems manufactures and sells cardiovascular diagnostic and interventional devices, including contrast injection systems (ACIST CVi and ACIST Pro), intravascular ultrasound imaging systems (ACIST HDi with Kodama catheters), and fractional flow reserve measurement systems (ACIST RXi with Navvus II microcatheters). These products are sold as capital equipment and disposable consumables to hospitals, cardiac catheterization laboratories, and interventional cardiologists for use in diagnostic and interventional cardiology, peripheral vascular, and structural heart procedures.

Product overview

ACIST Medical Systems, a Bracco Group company, provides a portfolio of diagnostic technologies for cardiovascular and peripheral vascular procedures. The product ecosystem centers on contrast management (ACIST Pro™, ACIST CVi®), intravascular imaging (ACIST HDi® with Kodama® catheter), and physiological assessment (ACIST RXi® with Navvus® II microcatheter and dPR feature). Products serve diagnostic and interventional cardiology, radiology, and vascular care across angiography, imaging, and physiology categories. The company operates from headquarters in Eden Prairie, Minnesota with European operations in the Netherlands and offices in Japan and Silicon Valley.

Differentiator

Problem solved

Functional benefit

Brands

  • ACIST CVi: Contrast Delivery System for managing contrast delivery and minimizing risk of contrast-induced acute kidney injury (CI-AKI) in interventional cardiology procedures.
  • ACIST HDi
  • ACIST RXi
  • ACIST RXi Mini
  • Navvus II
  • Kodama
  • ACIST Pro
  • ACIST dPR

Products and services

  • ACIST Pro Diagnostic System Next-generation variable-rate contrast management solution for image-guided cardiovascular procedures that builds on ACIST CVi technology to deliver automated contrast delivery with reduced contrast use and improved patient outcomes; for interventional cardiologists and cath lab teams.
  • ACIST CVi Contrast Delivery System Contrast Delivery System providing real-time, variable-flow control of contrast for precise and consistent contrast administration with built-in air column detection sensor alerts; for interventional cardiologists managing contrast volume and minimizing risk of contrast-induced acute kidney injury (CI-AKI).
  • ACIST HDi High-Definition IVUS System 60MHz high-definition intravascular ultrasound imaging system enabling optimized visualization for coronary and peripheral intervention strategy through three imaging modes (LumenView, SilkView, ClassicView) and an interactive compact console; for interventional cardiologists performing PCI optimization.
  • ACIST RXi Rapid Exchange FFR System Rapid Exchange Fractional Flow Reserve system with dPR (Diastolic Pressure Ratio) for physiological assessment of coronary disease using a monorail microcatheter and 0.014 inch guidewire of choice; for interventional cardiologists assessing coronary stenosis severity.
  • ACIST RXi Mini System Next-generation compact FFR measurement system engineered to integrate with hemodynamic systems and FFR software; for cath labs seeking simplified physiological assessment workflow.
  • Navvus II Rapid Exchange FFR MicroCatheter Rapid Exchange FFR MicroCatheter with improved flexibility, reduced lesion entry profile, and 0.014 inch guidewire compatibility for navigation of complex coronary artery disease; used with ACIST RXi system for physiological assessment.
  • Kodama HD IVUS Catheter HD IVUS Catheter with offset distal tip and VariFlex variable flexibility imaging window providing improved deliverability and optimized imaging for both coronary and peripheral vascular procedures; used with ACIST HDi console with 10x faster pullback at 10mm/sec.
  • ACIST Service and Support Contracts Multi-year technical support service packages including on-site assistance within 24 hours, next-day service loaner equipment, preventive maintenance, and upgrades for ACIST capital equipment installed in cath labs.

Quantifiable outcome

  • 45ml average reduction in contrast use
  • +10 more outcomes

Companies that use ACIST

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

ACIST technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

ACIST partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Bracco GroupcoreStrategic or Co-development PartnerACIST Medical Systems is a wholly-owned subsidiary of Bracco Group, a Milan-based international healthcare company and world leader in diagnostic imaging. Bracco Imaging S.p.A. acquired ACIST in 2001. Bracco Group has approximately 3,420 employees and annual consolidated revenues of around 1.29 billion euros with 86% from international sales.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

ACIST competitors and assessment

Company assessment

Emerging players

  • HeartFlow: HeartFlow provides non-invasive FFR-CT analysis as an alternative to catheter-based FFR measurement, targeting the same clinical decision point as ACIST's RXi/dPR platform but with a fundamentally different (imaging-based) delivery model.
  • CathWorks: CathWorks offers FFR-angio (cath lab-based non-invasive FFR) as a catheter-free alternative to traditional FFR measurement, representing emerging competitive pressure on ACIST's catheter-based physiology franchise.

Broad incumbents

  • GE HealthCare: GE HealthCare offers contrast media injectors (OptiStar, EmpowerCTA) and broad imaging/IT infrastructure for cath labs and interventional suites, overlapping with ACIST's contrast management and PACS integration offerings at a much larger scale.
  • Philips: Philips owns Volcano (IVUS/FFR) and offers Azurion interventional suites with integrated imaging and contrast injection, competing with ACIST across both the capital equipment and physiology/imaging consumables in the cath lab.
  • Bayer (Medrad): Medrad (Bayer) is one of the largest manufacturers of contrast media injectors (Mark 7 Arterion) and interventional radiology equipment, competing head-to-head with ACIST's CVi/Pro in hospitals and imaging centers worldwide.
  • Siemens Healthineers: Siemens Healthineers provides Artis interventional angiography systems, contrast injectors, and broad imaging IT that overlaps with ACIST's offerings in hospital cath lab and interventional radiology environments.

Direct peers

  • Boston Scientific: Boston Scientific competes directly with ACIST in intravascular imaging through its OptiCross IVUS and AVVIGO guidance system, serving the same interventional cardiology cath lab customers with overlapping procedure-driven utilization.
  • Opsens (Haemonetics): Opsens (acquired by Haemonetics) provides the OptoWire FFR measurement system, directly competing with ACIST's RXi/Navvus platform in catheter-based physiological assessment of coronary artery disease.
  • Guerbet: Guerbet is a leading contrast media and contrast injection systems manufacturer, directly competing with ACIST's CVi and Pro contrast management systems in hospital radiology and cardiology departments globally.
  • Abbott: Abbott competes with ACIST through its PressureWire FFR/iwFR physiology platform and OPTIS IVUS/OCT imaging systems, serving the same interventional cardiology procedure workflow with comparable catheter-based diagnostic offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ACIST social profiles

Digital presence

ACIST compliance and trust

Trust signal

Compliance2 records

ACIST financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ACIST leadership team

Management profile

Number of profiles

Profiles12 records

ACIST funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ACIST M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACIST

What does ACIST do?

ACIST Medical Systems manufactures and sells cardiovascular diagnostic and interventional devices, including contrast injection systems (ACIST CVi and ACIST Pro), intravascular ultrasound imaging systems (ACIST HDi with Kodama catheters), and fractional flow reserve measurement systems (ACIST RXi with Navvus II microcatheters). These products are sold as capital equipment and disposable consumables to hospitals, cardiac catheterization laboratories, and interventional cardiologists for use in diagnostic and interventional cardiology, peripheral vascular, and structural heart procedures.

Is ACIST a public or private company?

ACIST is a private company. It is classified as corporate owned and is currently operating.

When was ACIST founded?

ACIST was founded in 1991. It employs 251 to 500 people.

Where is ACIST based?

ACIST is headquartered in Eden Prairie, United States, in the North America region.

How does ACIST make money?

Four revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are consumable Catheters, service and Support Contracts and technical Support Services.

Who are ACIST's main competitors?

Emerging players on record are HeartFlow and CathWorks. Broad incumbents are GE HealthCare, Philips, Bayer (Medrad) and Siemens Healthineers. Direct peers are Boston Scientific, Opsens (Haemonetics), Guerbet and Abbott.

Does ACIST have an API?

No public API is recorded for ACIST.

What industry is ACIST in?

ACIST's product category is Interventional Cardiology Medical Devices. Its primary akta.pro industry code is HLAHABAK, Contrast Media Injectors & Radiology Accessories, with a secondary code of HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cardiovascular BusinessFDA clears next-gen contrast management system for the cath labAcist Medical Systems, a Minnesota-based Bracco company, has received FDA clearance for its Acist Pro Diagnostic System, a next-generation contrast management technology for cardiac catheterization labs, and has officially launched it in the United States after prior launches in Japan and Europe. The system features real-time contrast tracking, customizable presets, and delivers approximately 33% faster performance, up to 30% reduction in contrast-induced acute kidney injury risk, and 96% reduction in user radiation exposure compared to the previous model. Bracco Imaging CEO Fulvio Renoldi Bracco stated the launch marks an important milestone for the company and for advancing precision imaging in cath labs.PR NewswireBracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic SystemACIST Medical Systems, a Bracco company, announced U.S. FDA clearance and launch of the ACIST Pro™ Diagnostic System, a next-generation contrast management solution for image-guided cardiovascular procedures. The system, which builds on the company's existing ACIST CVi® technology, demonstrated clinical outcomes including an average 45ml reduction in contrast use, a 30 percent reduction in contrast-induced acute kidney injury, and five minutes saved per procedure. ACIST Pro™ was first introduced in Japan in 2025 and subsequently launched in European markets following CE mark approval in February 2026.BioSpaceBracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic SystemBracco and ACIST Medical Systems announced U.S. FDA clearance and launch of the ACIST Pro Diagnostic System, a variable-rate contrast management solution for interventional cardiology. The system builds on ACIST CVi, which previously reduced contrast use by 45ml and CI-AKI by 30% on average. It was first introduced in Japan in 2025 and launched in select European markets in February 2026.AuntMinnieEuropeBracco launches ACIST Pro in EuropeBracco Group's subsidiary, ACIST Medical Systems, is launching the ACIST Pro Diagnostic System in select European markets following its CE Mark approval under the MDR. The system, designed for cardiovascular procedures, replaces manual contrast delivery with automated technology and was first introduced in Japan in 2025.PR NewswireBracco and ACIST Medical Systems Announce European Launch of ACIST Pro™ Diagnostic SystemACIST Medical Systems, a Bracco Group company, announced the European launch of its ACIST Pro™ Diagnostic System, a next-generation variable-rate contrast management solution for image-guided cardiovascular procedures, following CE Mark approval under the European Medical Device Regulation. The system is an evolution of the ACIST CVi® technology and was first introduced in Japan in 2025, with FDA 510(k) clearance pending in the United States. Bracco and ACIST are positioning the launch as advancing their shared mission in interventional cardiology, radiology, and vascular care.MorningstarBracco and ACIST Medical Systems Announce European Launch of ACIST Pro™ Diagnostic SystemBracco Imaging and its subsidiary ACIST Medical Systems announced the European launch of the ACIST Pro™ Diagnostic System, a next-generation variable-rate contrast management solution for image-guided cardiovascular procedures, following CE Mark approval under the European Medical Device Regulation. The system, which builds on the ACIST CVi® platform, demonstrated clinical benefits including an average 45ml reduction in contrast use, a 30 percent reduction in contrast-induced nephropathy, and five minutes saved per procedure. Global availability is expected to expand throughout 2026, with FDA 510(k) clearance still pending in the United States.BioSpaceBracco and ACIST Medical Systems Announce European Launch of ACIST Pro™ Diagnostic SystemACIST Medical Systems, a Bracco Group company, announced the European launch of the ACIST Pro™ Diagnostic System in selected markets, a next-generation variable-rate contrast management solution for image-guided cardiovascular procedures that received CE Mark approval under the European Medical Device Regulation. The system builds on the clinical success of its predecessor ACIST CVi®, which demonstrated on average a 45ml reduction in contrast use, a 30 percent reduction in contrast-induced nephropathy, and five minutes saved per procedure. The ACIST Pro™ system was first introduced in Japan in 2025 with additional global availability expected throughout 2026, while FDA 510(k) clearance remains pending in the United States.PR NewswireBracco and ACIST Medical Systems Announce European Launch of ACIST Pro™ Diagnostic SystemACIST Medical Systems, a Bracco Group company, announced the European launch of the ACIST Pro™ Diagnostic System, a next-generation variable-rate contrast management solution for image-guided cardiovascular procedures, following CE Mark approval under the European Medical Device Regulation. The system is an evolution of the ACIST CVi®, which demonstrated clinical benefits including an average 45ml reduction in contrast use, a 30 percent reduction in contrast-induced nephropathy, and five minutes saved per procedure. The ACIST Pro™ system was first introduced in Japan in 2025, with additional global availability expected throughout 2026 and FDA 510(k) clearance still pending in the United States.PR NewswireGlobal Fractional Flow Reserve Market Outlook & Forecast to 2027 - Featuring Abbott, Acist Medical Systems and Boston Scientific Among OthersResearch and Markets has published a global fractional flow reserve (FFR) market outlook and forecast for 2022-2027, highlighting FFR as a gold standard for assessing coronary artery disease during invasive coronary angiography. The report identifies key growth drivers including an increasing target population suffering from cardiovascular diseases, rising obesity and metabolic conditions, and an aging global population, while noting that vendors like Boston Scientific, Philips, and ACIST Medical Systems are launching next-generation non-invasive FFR products incorporating AI and machine learning. Key players profiled in the report include Abbott, ACIST Medical Systems, Boston Scientific, CathWorks, GE Healthcare, Koninklijke Philips, Opsens, Siemens Healthineers, and HeartFlow.GlobeNewswireThe global fractional flow reserve market is expected to grow at a CAGR of 12% during 2022-2027The global fractional flow reserve market is projected to grow at a 12% CAGR from 2022 to 2027, driven by rising cardiovascular disease and non-invasive FFR adoption. North America leads the market, while APAC is expected to see the highest growth. Key vendors include Boston Scientific, Philips, and ACIST Medical Systems.